FLUZONE HIGH-DOSE QUADRIVALENT AND FLUBLOK QUADRIVALENT CAN HELP PREVENT FLU-RELATED HOSPITALIZATIONS1,2

Fluzone High-Dose Quadrivalent and Flublok Quadrivalent are the only higher-dose flu shots proven to prevent more flu in older adults than a standard-dose influenza vaccine in RCT.4,5

In a randomized, controlled efficacy trial, Fluzone High-Dose (Influenza Vaccine) trivalent formulation provided 24% (95% CI: 10-37) better protection against influenza due to any lab-confirmed circulating strains vs a standard-dose influenza vaccine in adults 65 years of age and older.1,5

The efficacy of the trivalent formulation is relevant to Fluzone High-Dose Quadrivalent since both vaccines are manufactured according to the same process and have overlapping compositions.1

Solicited systemic adverse reactions and solicited injection-site reactions were slightly more frequent with Fluzone High-Dose as compared to a standard-dose influenza vaccine.6

CI=confidence interval.

Click here for full efficacy and safety data.

In a randomized, controlled efficacy trial, Flublok Quadrivalent provided 30% (95% CI: 10-47) better protection against influenza due to any PCR-confirmed circulating strains vs a standard-dose quadrivalent inactivated influenza vaccine in adults 50 years of age and older.2,4

In adults 50 years of age and older, the most common (≥10%) injection-site reactions were tenderness (34%) and pain (19%); the most common (≥10%) solicited systemic adverse reactions were headache (13%) and fatigue (12%).2

Click here for full efficacy and safety data.

PCR=polymerase chain reaction.
external link icon ORDER VACCINES NOW
vaccine icon These vaccines and their administration are covered by Medicare and most commercial insurers.a

aThe information above is available at CMS.gov. The information is provided for informational purposes only and is not a guarantee of coverage. The information is gathered from various resources and is subject to change.

You are about to leave SanofiFlu.com

Would you like to continue?

CLOSE WINDOW

Reservations are
NOW OPEN!

Would you like to reserve your Sanofi flu vaccines for the 2024-2025 season?

By clicking “YES” you will be redirected to VaccineShop.com.

MAT-US-2309227-v1.0-11/2023

CLOSE WINDOW

INDICATIONS

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are vaccines indicated for active immunization against disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. Fluzone Quadrivalent is approved for use in persons 6 months of age and older. Flublok Quadrivalent is approved for use in persons 18 years of age and older. Fluzone High-Dose Quadrivalent is approved for use in persons 65 years of age and older.

IMPORTANT SAFETY INFORMATION

arrow down

Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine (including egg protein for Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent). In addition, Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent should not be administered to anyone who has had a severe allergic reaction after previous dose of any influenza vaccine.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.

If Guillain-Barré syndrome has occurred within 6 weeks following previous influenza vaccination, the decision to give Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent should be based on careful consideration of the potential benefits and risks.

If Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent are administered to immunocompromised persons, including those receiving immunosuppressive therapy, the immune response may be lower than expected.

Vaccination with Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent may not protect all recipients.

Syncope (fainting) has been reported following vaccination with Fluzone Quadrivalent and Fluzone High-Dose Quadrivalent. Procedures should be in place to avoid injury from fainting.

For Fluzone Quadrivalent, in children 6 months through 35 months of age, the most common injection-site reactions were pain or tenderness, erythema, and swelling; the most common solicited systemic adverse reactions were irritability, abnormal crying, malaise, drowsiness, appetite loss, myalgia, vomiting, and fever. In children 3 years through 8 years of age, the most common injection-site reactions were pain, erythema, and swelling; the most common solicited systemic adverse reactions were myalgia, malaise, and headache. In adults 18 years and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Flublok Quadrivalent, in adults 18 through 49 years of age, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache, fatigue, myalgia, and arthralgia. In adults 50 years of age and older, the most common injection-site reactions were tenderness and pain; the most common solicited systemic adverse reactions were headache and fatigue.

For Fluzone High-Dose Quadrivalent, in adults 65 years of age and older, the most common injection-site reaction was pain; the most common solicited systemic adverse reactions were myalgia, headache, and malaise.

For Fluzone Quadrivalent, Flublok Quadrivalent, and Fluzone High-Dose Quadrivalent, other adverse reactions may occur.

Before administration, please see the full Prescribing Information for Fluzone Quadrivalent, Flublok Quadrivalent, or Fluzone High-Dose Quadrivalent . Also, please see complete Patient Information for Fluzone Quadrivalent or Fluzone High-Dose Quadrivalent .

Click here to learn more about Sanofi’s commitment to fighting counterfeit drugs.

brands